Supplementary Table 1a

|  |
| --- |
| HPV status of invasive squamous cell carcinomas by p16 immunohistochemistry with regard to tumor characteristics in evaluable cases\*\* |
|  |  |  |  |
| Characteristics | p16 negative (n) | p16 positive (n) | p\*\*\* |
| pTX | 2 | 0 | 0,14 |
| pT1a | 10 | 13 |  |
| pT1b | 3 | 4 |  |
| pT2 | 14 | 9 |  |
| pT3 | 0 | 3 |  |
| pT4 | 0 | 2 |  |
| pNX | 14 | 24 | 0,04 |
| pN0 | 10 | 3 |  |
| pN1, pN2, pN3 | 5 | 4 |  |
| LX | 1 | 0 | 0,75 |
| L0 | 23 | 24 |  |
| L1 | 5 | 7 |  |
| VX | 1 | 0 | 0,49 |
| V0 | 25 | 29 |  |
| V1 | 3 | 2 |  |
| PnX | 1 | 0 | 0,576 |
| Pn0 | 25 | 28 |  |
| Pn1 | 3 | 3 |  |
| G1 | 10 | 2 | 0,023 |
| G2 | 16 | 23 |  |
| G3 | 3 | 6 |  |
| usual morphology | 27 | 27 | 0,672 |
| basaloid morphology | 2 | 4 |  |
| infiltrative pattern | 17 | 21 | 0,593 |
| pushing borders | 12 | 10 |  |
|  |  |  |  |
| \*\* only cases are reported with known tumour characteristics |
| \*\*\*Fisher-Freeman-Halton's exact contingency table-test |

Supplementary Table 1b

|  |
| --- |
| HPV status by Sanger sequencing technique with regard to tumor characteristics in evaluable cases\*\* |
|  |  |  |  |
| Characteristics | HPV high risk negative (n) | HPV high risk positive (n) | p\*\*\* |
| pTX | 2 | 0 | 0,120 |
| pT1a | 14 | 9 |  |
| pT1b | 4 | 3 |  |
| pT2 | 20 | 2 |  |
| pT3 | 2 | 1 |  |
| pT4 | 2 | 0 |  |
| pNX | 23 | 14 | 0,010 |
| pN0 | 13 | 0 |  |
| pN1, pN2, pN3 | 8 | 1 |  |
| LX | 1 | 0 | 0,785 |
| L0 | 33 | 13 |  |
| L1 | 10 | 2 |  |
| VX | 1 | 0 | 1,000 |
| V0 | 39 | 14 |  |
| V1 | 4 | 1 |  |
| PnX | 1 | 0 | 0,488 |
| Pn0 | 38 | 15 |  |
| Pn1 | 5 | 0 |  |
| G1 | 10 | 2 | 0,902 |
| G2 | 28 | 11 |  |
| G3 | 6 | 2 |  |
| usual morphology | 40 | 13 | 0,638 |
| basaloid morphology | 4 | 2 |  |
| infiltrative pattern | 29 | 8 | 0,537 |
| pushing borders | 15 | 7 |  |
|  |  |  |  |
| \*\* only cases are reported with known tumour characteristics |
| \*\*\*Fisher-Freeman-Halton's exact contingency table-test |